JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Eugene A. Grossi
Gregory A. Crooke
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossi, E. A.
Right arrow Articles by Crooke, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossi, E. A.
Right arrow Articles by Crooke, G. A.
Related Collections
Right arrow Cardiac - other
Right arrow Congestive Heart Failure
Right arrow Valve disease
Right arrowRelated Article

J Thorac Cardiovasc Surg 2006;132:455-456
© 2006 The American Association for Thoracic Surgery

Editorial

Mitral valve surgery in heart failure: Insights from the Acorn clinical trial

Eugene A. Grossi, MD*, Gregory A. Crooke, MD

Department of Cardiothoracic Surgery, NYU School of Medicine, New York, NY.

Received for publication April 27, 2006; accepted for publication May 3, 2006.

* Address for correspondence: Eugene A. Grossi, MD, New York University Medical Center, Department of Surgery, 530 First Ave, Suite 9V, Skirball Bldg, New York, NY 10016 (Email: grossi@cv.med.nyu.edu).

The first 20% of the full text of this article appears below.

GoIn this issue of the Journal, Acker and colleagues1Go present some of the outcomes of the CorCap study—specifically, the subgroup analysis of patients who underwent concomitant mitral valve surgery. In this randomized study, the addition of the CorCap device provided enhanced geometric changes in the left ventricular (LV) shape without having a significant additive effect on clinical outcomes.

The most notable information contained in this dataset is the outcomes of the control group: mitral valve surgery in medically optimized patients with significant functional mitral regurgitation, myopathic hearts, and symptomatic congestive heart failure. This subgroup represents an uncontrolled prospective analysis of isolated mitral valve surgery in patients with significant functional mitral insufficiency, New York Heart Association class III or IV, ejection fraction less than 35% (mean ejection fraction, 23% ± 9%), and a dilated LV (mean . . . [Full Text of this Article]


Related Article

Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial
Michael A. Acker, Steven Bolling, Richard Shemin, James Kirklin, Jae K. Oh, Douglas L. Mann, Mariell Jessup, Hani N. Sabbah, Randall C. Starling, Spencer H. Kubo for the Acorn Trial Principal Investigators and Study Coordinators
J. Thorac. Cardiovasc. Surg. 2006 132: 568-577. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.